In pregnancy, 'total nicotine equivalents' (TNE) and 'total' cotinine (TC) concentrations reflect nicotine (tobacco smoke) exposure more accurately than the widely used biomarker, 'free' cotinine. Although the number of cigarettes smoked daily (CPD) is similarly a poor proxy for such exposures, this measure can still be useful in population surveys.
Taghavi and colleagues compare three measures of smoking: self-reported smoking, urinary concentrations of the nicotine biomarker cotinine and urinary concentrations of 'total nicotine equivalents' (TNE), a more comprehensive measure of both nicotine and its metabolites. They then use this comparison to assess the utility of each for measuring nicotine exposure in pregnant women [1] . The TNE measure was used as a 'gold standard' against which other measures were judged, because it reflects up to 88% of nicotine intake [2] and is not influenced by pregnancy-induced acceleration in the metabolism of nicotine and cotinine [3] . Using the TNE measure, nicotine exposure was similar in early and late pregnancy (approximately 13 and 30 weeks) but much higher by approximately 25 weeks postpartum [1] , presumably because women who had stopped smoking in pregnancy re-started smoking afterwards. Most nicotine is metabolized to cotinine [4] so, unsurprisingly, free cotinine levels showed a similar pattern; however, due to the faster metabolism of cotinine in pregnancy [5, 6] , these levels were correlated less strongly with TNE during gestation. Consequently, free cotinine measurements would have underestimated nicotine exposures by 55% in early and 65% in late pregnancy. In contrast, total cotinine (free cotinine and cotinine glucuronide combined) was correlated more strongly with TNE, and this correlation remained consistent during and after pregnancy and also in women with faster and slower nicotine metabolisms, suggesting that total cotinine levels reflect nicotine exposures as accurately as do TNE levels.For women who smoke in pregnancy and who do not use nicotine replacement therapy or e-cigarettes, all nicotine exposure comes from tobacco smoke and any measure which predicts nicotine intake accurately also predicts heaviness of smoking and of tobacco smoke toxin exposure. Accordingly, Taghavi et al.'s findings have implications for how such exposures might be validated in observational cohort studies investigating fetal, infant and maternal harms from smoking in pregnancy. Free cotinine (FC), a frequently used biomarker, underestimates nicotine exposure. TNE and total cotinine (TC) are the most accurate exposure biomarkers, and future studies using either would minimize 'noise' incurred during exposure measurement, maximizing the chances of detecting valid associations between exposure in pregnancy and outcomes. Hitherto unidentified dose-response relationships between smoking in pregnancy and adverse outcomes might become apparent, and better quantification of known risks from smoking in pregnancy may be possible. For example, using free cotinine, a biomarker which Taghavi et al. show reflects nicotine less closely than others, it has been shown recently that there is no 'safe' level of second-hand smoking, as children with the very lowest detectable urinary free cotinine levels had poorer asthma outcomes than those with no measurable urinary free cotinine [7] . More sensitive quantification of tobacco smoke exposure in pregnancy using biomarkers such as TNE and total cotinine could lead to other, novel insights, potentially with substantial public health implications. Due to discrepancies between numbers of cigarettes smoked daily [cigarettes per day (CPD)] and TNE, Taghavi et al. rightly question the use of CPD to measure nicotine exposure [1] . In a smoking cessation trial such as theirs [8] , one might expect women who do not quit to report a lower CPD when asked later in pregnancy. The authors cite other reports of reduced CPD in late pregnancy, and suggest that there is also bias against women admitting how heavily they smoke operating in those studies. However, in those survey studies such bias is probably less important, as there is no expectation, apart from the usual societal expectations, that participants should stop smoking during pregnancy, whereas cessation trials generally recruit women who are committed to stopping smoking. Hence, trial participants may perceive greater pressure to report changes in smoking behaviour at follow-up. Behavioural surveys are generally cross-sectional [9] and, as some participants are inevitably lost to follow-up, respondents at baseline and follow-up may not be the same women; bias arising from such attrition could be more influential. To my knowledge, there is only one survey of pregnant women's smoking behaviour which has reported longitudinal CPD data at different times in pregnancy and which adjusts these for loss to follow-up [10] . This showed very similar CPD levels in early and late pregnancy and also in the postpartum period [10] . Another longitudinal study reported movement between different categories of smoking heaviness as pregnancy progressed but, similarly, did not reveal a trend towards lighter smoking in later pregnancy either [11] . Perhaps the problem is less with the CPD measure itself and more a function of the design and analysis of studies using it? CPD may not be a great exposure measure, but it is cheap and easily administered and very probably remains a valid measure of smoking behaviour in pregnancy provided that the biases inherent in collecting self-report data on this socially undesirable habit are understood.
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